BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report-Reference-Cited by-同舟云学术

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report

Published:2023-04 Issue:2 Volume:115 Page:107-110
ISSN:1591-951X
Container-title:Pathologica
language:
Short-container-title:Pathologica

Author:

Buttitta Fiamma,Di Marino Pietro,Felicioni Lara,Primavera Francesca Chiara,Ferro Benedetta,Zampacorta Claudia,Pasciuto Maria Paola,Rossetti Rebecca,Tudini Marianna,Marchetti Antonio,D’Angelo Emanuela

Publisher

Siapec Servizi Srl

Subject

Pathology and Forensic Medicine

Reference5 articles.

1. Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 2018;80:11-27. https://doi.org/10.1016/j.humpath.2018.06.018. Epub 2018 Jun 23. PMID: 29944973.

2. Gadducci A, Guerrieri ME. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Crit Rev Oncol Hematol 2017;114:153-165.

3. Baert T, Ferrero A, Sehouli J, et al. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol 2021;32:710-725. https://doi.org/10.1016/j.annonc.2021.02.015. Epub 2021 Mar 3. PMID: 33675937.

4. Wu Y, Xu S, Cheng S, et al. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res 2023;16:6. https://doi.org/10.1186/s13048-023-01094-5. PMID: 36611214; PMCID: PMC9826575.

5. AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov 2017;7:818-831. https://doi.org/10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1. PMID: 28572459; PMCID: PMC5611790.